Kali: metabolic research components and what remains unproven

A woman lacing her shoes on warm stone steps before a morning walk

Kali is a named combination of BPC-157, MOTS-C, 5-Amino-1MQ, and tesamorelin. Its components come from tissue signalling, mitochondrial, enzyme inhibition, and growth hormone research respectively. No human study of the combination was identified, and two components have essentially no human evidence at all.

Composition

  • bpc-157
  • mots-c
  • 5-amino-1mq
  • tesamorelin

Overview

Kali brings together four substances from four different research literatures. Only one has an FDA-approved product in any indication. Two are studied mainly in cells and animals, and one is an oral-research small molecule rather than a peptide in the conventional sense. Presenting them as a single named product creates an impression of coherence that the underlying research does not support, which is the main thing a reader should take from this page.

Why these are grouped

The stated rationale is metabolic breadth: an enzyme inhibitor studied in fat cell metabolism, a mitochondrial-derived peptide, a repair-signalling peptide, and a growth hormone releasing analogue with human visceral fat data in one narrow indication. Four different mechanisms is a marketing argument for coverage. It is not evidence that the mechanisms cooperate.

What each ingredient contributes

bpc-157

Studied in animal models of tissue and gut signalling. Included for recovery interest rather than for any human metabolic finding.

mots-c

A mitochondrial-derived peptide studied in animal models of metabolic signalling, with minimal human data.

5-amino-1mq

A small molecule studied in cell and animal models as an NNMT enzyme inhibitor in fat metabolism research. Human trial data are lacking.

tesamorelin

The only component with an FDA-approved product, for reduction of excess abdominal fat in HIV-associated lipodystrophy, an indication that does not extend to general weight management.

Combination evidence

  • No human study of the Kali combination was identified.
  • No published data describe interactions among these four substances.
  • Three of the four components have no adequate human efficacy data individually, which limits what can be said even before the combination question is raised.

Tesamorelin's human data belong to a specific approved indication in people with HIV-associated lipodystrophy and do not generalise to metabolic health in the wider population. The other three components rest on preclinical work. Extrapolating from mouse metabolic models to a human outcome is a hypothesis, not a finding.

Preclinical rationale

  • NNMT inhibition appears in rodent models of adipose metabolism.
  • Mitochondrial-derived peptides appear in animal work on metabolic signalling and exercise biology.
  • Growth hormone releasing analogues have human data on visceral fat in a specific clinical population.

What is not established

  • Whether any metabolic change occurs in humans from three of the four components.
  • Whether the combination affects weight, body composition, or metabolic markers.
  • Interaction effects between an enzyme inhibitor and growth hormone axis stimulation.
  • Safety of the combination at any duration.

Questions to discuss with a physician

  • Does anything here have human evidence relevant to my metabolic goals?
  • How would this interact with the medicines I already take?
  • What metabolic laboratory work would you want to see first?
  • What established options should I exhaust before considering this?
  • How would we know it is not working?

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-15.